Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
Portfolio Pulse from
Biohaven's NDA for Troriluzole in spinocerebellar ataxia has been accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. Additionally, BHV-7000 is being studied for bipolar disorder and MDD, with data expected in 2025. The global MDD treatment market is projected to reach $14.96 billion by 2032.
February 11, 2025 | 11:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biohaven's Troriluzole received FDA Priority Review, indicating a potential approval in Q3 2025. BHV-7000 is also in trials for bipolar disorder and MDD, with results expected in 2025.
The FDA's Priority Review for Troriluzole suggests a faster approval process, which is positive for Biohaven. Additionally, the ongoing studies for BHV-7000 in significant mental health conditions could lead to future growth, especially given the projected market size for MDD treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100